GeneDx Holdings Corp vs State Street PDR S&P Retail ETF — how do they compare? GeneDx Holdings Corp trades at $61.92 (market cap $1.80B), while State Street PDR S&P Retail ETF trades at $88.47. The key difference: State Street PDR S&P Retail ETF is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| WGS | XRT | |
|---|---|---|
Market Cap | $1.80B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $167.51 | $90.88 |
52-Week Low | $34.51 | $77.28 |
Enterprise Value | $1.80B | — |
Signals from Pluang's Aura AI — not financial advice
GeneDx Holdings (WGS) trades at $60.65, down 4.46% today, amid a bearish technical signal and multiple class-action lawsuits alleging securities fraud. The stock shows weak fundamentals with a negative net income margin of -17.58% and ROE of -30.42%, though it beat EPS estimates in two of the last three quarters. Revenue grew to $427.54M in 2025 but profitability remains a challenge, with a high EV/EBITDA of 161.17 indicating stretched valuation relative to earnings.
Despite a 90.9% analyst buy rating and a $75.40 consensus price target, significant risks from litigation and persistent losses cloud the outlook. The stock faces near-term pressure from legal overhangs, while operational cash flow turned negative in 2026. Investors should weigh high analyst optimism against substantial fundamental and legal headwinds before considering a position.
XRT trades at $88.94, down 0.54% today, with a bullish technical signal from moving averages and neutral oscillators. Support levels are at $87-$88, resistance at $90-$91. The ETF tracks the retail sector, which shows mixed consumer sentiment amid rising energy costs and slowing inflation. Recent retail sales growth has been positive but decelerating, with June up 0.2% after May's 1.0% gain (Census Bureau, June 2026).
Outlook is cautious due to macroeconomic pressures on consumer spending, though the ETF's diversification offers stability. Risks include inflation volatility and weak consumer confidence. Analyst sentiment is mixed, with some downgrades citing headwinds. The technical setup suggests near-term consolidation between support and resistance levels.
Trailing returns across standard periods
Latest headlines on both assets
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →XRT is an equal-weighted ETF that tracks the U.S. retail sector. It provides diversified exposure to apparel, automotive, and online retailers, including well-known names like Amazon, Target, and Costco.
Read more on XRT →